3-Day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: Multicentre, randomised and controlled trial in adults and children

British Journal of Ophthalmology

Volumn 91, Issue 4, 2007, Pages 465-469

  Cochereau, Isabelle ^a   Meddeb Ouertani, Amel ^b   Khairallah, Moncef ^c   Amraoui, Abdelouahed ^d   Zaghloul, Khalid ^d   Pop, Mihai ^e   Delval, Laurent ^f   Pouliquen, Pascale ^f   Tandon, Radhika ^g   Garg, Prashant ^h   Goldschmidt, Pablo ⁱ   Bourcier, Tristan ⁱ  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

^c FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^d IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^e Neurosurgery Dept   (Romania)

^f Laboratoires Thea   (France)

^g ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^h L V PRASAD EYE INSTITUTE   (India)

ⁱ Hopital des XV XX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; AZYTER; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BACTERIUM CULTURE; BURN; BURNING SENSATION; CHILD; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEWBORN; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; CHILD, PRESCHOOL; CONJUNCTIVITIS, BACTERIAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; SINGLE-BLIND METHOD; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 34247197036     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.103556     Document Type: Article

References (37)

1. Syed NA, Chandler JW. Bacterial conjunctivitis. In:Infecfions of the eye.In: Tabbara KF, Hyndiuk RA, eds. Boston, USA: Little, Brown and Co, 1996;27:423-31.
2. Anonymous. Centers for Disease Control and Prevention. Pneumococcal conjunctivitis at an elementary school - Maine, September 20-December 6, 2002. JAMA 2003;289:1097-8.
3. Martin M, Turco JH, Zegans ME, et al. An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med 2003;348:1112-21.
4. Hwang DG. Bacterial conjunctivitis. In:Ocular infection & immunity.In: Pepose JS, Holland GN, Wilhelmus KR, eds. Saint-Louis, USA: Mosby, 1996;62:799-817.
5. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract 2001;51:473-7.
6. Sheikh A, Hurwitz B, Cave J. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev 2000;2: CD001211.
7. Sheikh A, Hurwitz B. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev, 2006;CD001211.
8. Hwang DG, Schanzlin DJ, Rotberg MH, et al. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Br J Ophthalmol 2003;87:1004-9.
9. Sheikh A. Acute bacterial conjunctivitis. In:Evidence-based ophthalmology.In: Wormald R, Smeeth L, Henshaw K, eds. London, United Kingdom: BMJ Books, 2004;5:33-5.
10. Jaruratanasirikul S, Hortiwakul R, Tantisarasart T, et al. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob Agents Chemother 1996;40:825-6.
11. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987;31:1939-47.
12. Van Bambeke F, Tulkens PM. Macrolides: pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 2001;18:S17-S23.
13. Tabbara KF, al Kharashi SA, al Mansouri SM, et al. Ocular levels of azithromycin. Arch Ophthalmol 1998;116:1625-8.
14. Bryskier A, Bergogne-Bérézin E. Macrolides. In:Antibiotiques, agents antibacteriens et antifongiques.In: Bryskier A, eds. Paris, France: Ellipses, 1999;18:499-562.
15. Drew RH, Gallis HA. Azithromycin-spectrum of activity, pharmacokinetics, and clinical applications. Pharmacotherapy 1992;12:161-73.
16. Fechner PU, Teichmann KD. The conjunctiva. In:Ocular therapeutics pharmacology and clinical application.In: Fechner PU, Teichmann KD, eds. Thorofare, USA: Slack Inc, 1998;15:285-326.
17. Morrow GL, Abbott RL. Conjunctivitis. Am Fam Physician 1998;57:735-46.
18. Soukiasian SH, Baum J. Bacterial conjunctivitis. 2nd Edn.In:Cornea.In: Krachmer JH, Mannis MJ, Holland EJ, eds. Philadelphie, USA: Elsevier Mosby, 2005;49:615-28.
19. Milazzo G, Papa V, Carstocea B, et al. Topical netilmicin compared with tobramycin in the treatment of external ocular infection. Int J Clin Pharmacol Ther 1999;37:243-8.
20. Bloom PA, Leeming JP, Power W, et al. Topical ciprofloxacin in the treatment of blepharitis and blepharoconjunctivitis. Eur J Ophmalmol 1994;4:6-12.
21. Cagle G, Davis S, Rosenthal A, et al. Topical tobramycin and gentamicin sulfate in the treatment of ocular infections: multicenter study. Curr Eye Res 1981;1:523-34.
22. Cagle GD, Abshire RL. Quantitative ocular bacteriology: a method for the enumeration and identification of bacteria from the skin-lash margin and conjunctiva. Invest Ophthalmol Vis Sci 1981;20:751-7.
23. Gwon A. Ofloxacin vs tobramycin for the treatment of external ocular infection. Ofloxacin Study Group II. Arch Ophthalmol 1992;110:1234-7.
24. Jacobson JA, Call NB, Kasworm EM, et al. Safety and efficacy of topical norfloxacin versus tobramycin in the treatment of external ocular infections. Antimicrob Agents Chemother 1988;32:1820-4.
25. Jauch A, Fsadni M, Gamba G. Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis. Graefes Arch Clin Exp Ophthalmol 1999;237:705-13.
26. Fioretti GM, Campanari C. Le congiuntiviti di origine batterica in eta pediatrica. Trattamento antibiotico locale con tobramicina collirio. Pediatr Med Chir 1989;11:421-3.
27. Gallenga PE, Lobefalo L, Colangelo L, et al. Topical lomefloxacin 0.3% twice daily versus tobramycin 0. 3% in acute bacterial conjunctivitis: a multicenter double-blind phase III study, Ophthalmologica 1999;213:250-7.
28. Gross RD, Hoffman RO, Lindsay RN. A comparison of ciprofloxacin and tobramycin in bacterial conjunctivitis in children. Clin Pediatr (Phila) 1997;36:435-44.
29. Jackson WB, Low DE, Dattani D, et al. Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops. Can J Ophthalmol 2002;37:228-37.
30. Leibowitz HM, Hyndiuk RA, Smolin GR, et al. Tobramycin in external eye disease: a double-masked study vs. gentamicin. Curr Eye Res 1981;1:259-66.
31. Leibowitz HM. Antibacterial effectiveness of ciprofloxacin 0.3% ophthalmic solution in the treatment of bacterial conjunctivitis. Am J Ophthalmol 1991;112:29S-33S.
32. Lichtenstein SJ, Rinehart M. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. J AAPOS 2003;7:317-24.
33. Rietveld RP, ter Riet G, Bindels PJ, et al. Predicting bacterial cause in infectious conjunctivitis: cohort study on informativeness of combinations of signs and symptoms. BMJ 2004;329:206-10.
34. Schwab IR, Friedlaender M, McCulley J, et al. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis. Ophthalmology 2003;110:457-65.
35. Yee RW, Tepedino M, Bernstein P, et al. A randomized, investigator-masked clinical trial comparing the efficacy and safety of gatifloxacin 0.3% administered BID versus QID for the treatment of acute bacterial conjunctivitis. Curr Med Res Opin 2005;21:425-31.
36. Tabbara KF, El Sheikh HF, Islam SM, et al. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%. Eur J Ophthalmol 1999;9:269-75.
37. Kernt K, Martinez MA, Bertin D, et al. A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis. Eur J Ophthalmol 2005;15:541-9.